O
steoporosis is a skeletal disorder characterized by compromised bone strength, increasing the risk for fracture (1) . Risk factors include, but are not limited to, increasing age, female sex, postmenopause for women, low body weight, parental history of a hip fracture, cigarette smoking, race, hypogonadism, certain medical conditions (particularly rheumatoid arthritis), and certain medications for chronic diseases (such as glucocorticoids).
During one's expected remaining life, 1 in 2 postmenopausal women and 1 in 5 older men are at risk for an osteoporosis-related fracture (2) . The increasing prevalence and cost of osteoporosis have heightened interest in the effectiveness and safety of the many interventions currently available to prevent osteoporotic fracture. In 2007, we conducted a systematic review of the comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis (3, 4) . Since that time, new drugs have been approved for treatment, and new studies have been published about existing drugs. Additional issues about pharmacologic treatments for osteoporosis that have become particularly salient include the optimal duration of therapy; the safety of long-term therapy; and the role of bone mineral density (BMD) measurement, both for screening and for monitoring treatment. Therefore, we updated our original systematic review.
METHODS
This article is a condensed and further updated version of an evidence review conducted for the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Centers program (5) . This article focuses on the comparative benefits and risks of short-and long-term pharmacologic treatments for low bone density. In addition, we address issues regarding monitoring and duration of therapy. For this updated review, we followed the same methods as our 2007 review, with a few exceptions. A protocol for this review was developed and posted on the Effective Health Care Program Web site (6) .
Food and Drug Administration's (FDA) MedWatch database, and relevant pharmacologic databases from 2 January 2005 to 3 June 2011. The search strategy followed that of the original report, with the addition of terms for new FDA-approved drugs (such as denosumab) and newly reported adverse events. The full search strategies are in our evidence report (5) . We later updated this search to 21 January 2013 and used a machine learning method that a previous study showed had high sensitivity for detecting relevant evidence for updating a search of the literature on osteoporosis treatments (7) and then updated the searches to 4 March 2014 using the full search strategy.
Study Selection
Eligible studies were systematic reviews and randomized, controlled trials (RCTs) that studied FDA-approved pharmacotherapy (excluding calcitonin and etidronate) for women or men with osteoporosis that was not due to a secondary cause (such as glucocorticoid therapy and androgen-deprivation therapy) and also measured fractures as an outcome at a minimum follow-up of 6 months. In addition, we included observational studies with more than 1000 participants for adverse events and case reports for rare events. As in our original review, only Englishlanguage studies were included.
Data Extraction and Quality Assessment
Reviews were done in duplicate by pairs of reviewers. Study characteristics were extracted in duplicate, and outcomes data (both benefits and harms) were extracted by the study statistician. Study quality was assessed as it was in the 2007 report using the Jadad scale for clinical trials (with several questions added to assess allocation concealment and other factors) and the Newcastle-Ottawa Scale for observational studies (8, 9) . Systematic reviews were assessed using a modified version of the 11 AMSTAR (A Measurement Tool to Assess Systematic Reviews) criteria (the modifications included eliminating the requirements to list all of the excluded studies and assess the conflicts of interest for all of the included studies) (10) . The assessments of efficacy and effectiveness used reduction in fracture (all, vertebral, nonvertebral, spine, hip, wrist, or other) as the outcome (studies reporting changes in BMD but not fracture were excluded).
Data Synthesis and Analysis
Evidence on efficacy and effectiveness was synthesized narratively. For adverse events, we pooled data as in the 2007 report: We compared agent versus placebo and agent versus agent for agents within the same class and across classes. For groups of events that occurred in 3 or more trials, we estimated the pooled odds ratio (OR) and its associated 95% CI. Because many events were rare, we used exact conditional inference to perform the pooling rather than applying the usual asymptotic methods that assume normality. StatXact PROCs software was used for the analysis (11, 12) . Large cohort and case-control studies were included to assess adverse events. Strength of evidence was assessed using the criteria of the Agency for Healthcare Research and Quality Evidence-based Practice Centers program, which are similar to those proposed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (13) .
Role of the Funding Source
The update that included studies identified in the 3 June 2011 search was funded by AHRQ. Subsequent updating received no external funding. Although AHRQ formulated the initial study questions for the original report, it did not participate in the literature search, determination of study eligibility criteria, data analysis, or interpretation of the data. Staff from AHRQ reviewed and provided comments on the report.
RESULTS
The first search yielded 26 366 titles, 2440 of which were considered potentially relevant ( Figure) . Of these, 661 full-text articles were reviewed, resulting in 255 articles that were included in the update report. Of these, 174 articles were relevant to this article. The second update search plus hand searching initially yielded 16 589 titles, and machine learning and full-text review identified 107 as relevant. The third update yielded 12 131 titles. After title, abstract, and full-text screening, 34 were relevant. Thus, 55 086 titles were screened and 315 articles met eligibility criteria for inclusion. Not every eligible study is cited in this article. A complete list of studies that met eligibility criteria is available at www.rand.org/health/centers/epc.
Fracture Prevention
Our previous review (3) identified 76 randomized trials and 24 meta-analyses and concluded that there was good-quality evidence that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid hormone, and raloxifene prevented osteoporotic fractures, although not all of these agents prevented hip fractures. The principal new efficacy findings since that time are additional data about zoledronic acid and data about a new agent, denosumab (Tables 1 and 2) . The data for zoledronic acid came from 6 placebo-controlled studies of various doses in postmenopausal women (14 -19) , the 2 largest of which enrolled 7230 women (15) and 2127 women (14) . Both studies showed statistically significant reductions in nearly all types of fractures assessed, with relative risk reductions ranging from 0.23 to 0.73 at time points from 24 to 36 months after initiation of treatment. The data for denosumab came from 2 placebo-controlled trials in postmenopausal women, one small (332 enrolled women) (20) and one much larger that followed 7521 women for 36 months (21) . This latter study found statistically significant reductions in each anatomical fracture type measured (hip, nonvertebral, vertebral, and new clinical vertebral), with hazard ratios of 0.31 to 0.80. Many secondary analyses and open-label extension results of this trial report the effectiveness of denosumab in various subpopulations and other circumstances (22) (23) (24) (25) (26) (27) (28) .
Despite some difficulties in comparing results across trials because of differences in the outcomes reported, high-strength evidence shows that bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), denosumab, and teriparatide (the 1,34 amino acid fragment of the parathyroid hormone) reduce fractures compared with placebo in postmenopausal women with osteoporosis, with relative risks for fractures generally in the range of 0.40 to 0.60 for vertebral fractures and 0.60 to 0.80 for nonvertebral fractures. This range translates into a number needed to treat of 60 to 89 to prevent 1 vertebral fracture and 50 to 67 to prevent 1 hip fracture over 1 to 3 years of treatment, using a pooled average of the incidence of these fractures in the placebo groups from included studies. The effect of ibandronate on hip fracture risk reduction is unclear because hip fracture was not a separately reported outcome in placebo-controlled trials of this agent. The selective estrogen receptor modulator raloxifene has been shown in placebo-controlled trials to reduce only vertebral fractures; reduction in the risk for hip or nonvertebral fractures was not statistically significant.
There is only one randomized, controlled trial of men with osteoporosis that was designed with a primary fracture reduction outcome. Nearly 1200 men with osteoporosis were randomly assigned to placebo or zoledronic acid intravenously once per year for 2 years. At follow-up, 1.6% of treated men had new radiologically detected vertebral fractures, compared with 4.9% of men treated with placebo, with a relative risk of 0.33 (95% CI, 0.16 to 0.70). 
Comparative Effectiveness
Head-to-head comparative effectiveness studies assessing fracture outcomes are rare, have either not reported statistical testing or fracture outcomes between groups (30), have not found significant differences (3), or have analyzed the comparisons on a per-protocol rather than an intention-to-treat basis (31, 32) . Thus, there have been several attempts to estimate comparative effectiveness using network meta-analysis and indirect or mixed treatment comparisons. A recent network meta-analysis of 116 placebo-controlled or head-to-head trials assessing alendronate, risedronate, ibandronate, zoledronic acid, raloxifene, denosumab, teriparatide, vitamin D, and calcium concluded that any of the drugs were likely more effective than vitamin D or calcium; the evidence supporting raloxifene was not as strong as the evidence for the other drugs; and differences in vertebral and nonvertebral fracture risk reduction among any of the bisphosphonates, denosumab, or teriparatide were not consistent or statistically significant (AMSTAR score, 10 of 11) (33).
A second network meta-analysis (AMSTAR score, 6 of 11) included 30 RCTs and found no significant differences in nonvertebral fracture risk in the indirect comparisons among alendronate, risedronate, etidronate, ibandronate, zoledronic acid, raloxifene, denosumab, teriparatide, or strontium, although the authors noted that etidronate, ibandronate, and raloxifene lack direct evidence of superiority to placebo in preventing nonvertebral fractures (34) .
A third network meta-analysis, both sponsored by and including coauthors from the manufacturer of one drug, included 21 studies and likewise found no statistically significant difference in indirect or mixed treatment comparisons in nonvertebral fracture risk reduction among alendronate, risedronate, etidronate, ibandronate, zoledronic acid, raloxifene, denosumab, teriparatide, or strontium. These authors also noted that etidronate, raloxifene, and ibandronate did not have direct evidence of a reduction in nonvertebral fractures relative to placebo (AMSTAR score, 7 of 11) (35) .
A fourth network meta-analysis (AMSTAR score, 3 of 11), this time assessing alendronate, risedronate, ibandronate, zoledronic acid, and denosumab and restricting inclusion to studies that reported clinical and morphometric vertebral fractures and had a treatment period of at least 3 OR ϭ odds ratio; RR ϭ risk ratio.
Review Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures years, included 9 RCTs and reported no statistically significant differences among drugs in the mixed treatment comparison (36) . A fifth network meta-analysis, sponsored by and including authors from the manufacturer of one drug, included 8 RCTs to assess the relative effectiveness of alendronate, ibandronate, risedronate, etidronate, and zoledronic acid on many fracture outcomes (AMSTAR score, 6 of 11). Other than the sponsor's drug and the outcome of morphometric vertebral fractures, this analysis did not find any consistent significant differences among drugs for the various fracture outcomes (37) .
All of these network meta-analyses are limited by the dearth of head-to-head studies; nevertheless, their conclusions are consistent with our narrative synthesis of the evidence. Raloxifene does not prevent nonvertebral fractures, and there is less evidence supporting nonvertebral fracture reduction efficacy for ibandronate than for the other bisphosphonates, denosumab, or teriparatide. Other differences in comparative effectiveness among drugs are likely to be small.
Adverse Events Atypical Subtrochanteric Fractures
An important new potential adverse event is the increased risk for atypical subtrochanteric fractures seen in patients treated with bisphosphonates ( Table 3) . At present, these associations come entirely from observational studies, and results are not completely consistent (38 -71 ). An increased risk has not been seen in clinical trials, although even an analysis of data aggregated from 3 large trials (a total of 14 195 women) was underpowered to detect an effect (pooled relative risk, 1.33 [CI, 0.12 to 14.7]) (61) . A systematic review of case and case series studies (AMSTAR score, 7 of 9) (66) identified 141 women with this fracture, and the FDA issued a warning about the possible link between bisphosphonate use and this adverse event (72) .
Since then, a recent meta-analysis of 5 case-control studies and 6 cohort studies (AMSTAR score, 10 of 11) found an overall pooled risk ratio of 1.70 (CI, 1.22 to 2.37) (73 (75) (52) . Use of denosumab has also been linked with atypical femoral fractures (26) .
Cancer
We found low-strength signals of potential associations with various types of cancer, but additional data are needed. Four large observational studies have assessed a possible association between the use of bisphosphonates and esophageal cancer, 2 of which reported an increased risk (76, 77) and 2 of which did not (78, 79) . Several large observational studies found that bisphosphonate use was associated with either no increased risk or, in some cases, a statistically significant decrease in the risk for all types of cancer in general (80 -83) and certain types of cancer, specifically breast (81), colon, and other gastrointestinal cancer (80, 84) . A meta-analysis of 4 studies (AMSTAR score, 8 of 11) concluded that there were statistically significantly increased odds (1.74) for esophageal cancer in patients 
Strength of Evidence Estimate of Effect
Monitoring is likely not needed in most women Moderate Patients with T-scores greater than Ϫ1.5 only rarely progress to osteoporosis in 15 y; patients receiving treatment benefit even if their BMD does not increase; the only reported benefit of monitoring on treatment is in women receiving alendronate for 5 y who had a vertebral fracture at baseline How long to treat is unknown, but high-risk patients may benefit from treatment longer than 5 y Low Reported benefit of treatment beyond 5 y is greatest in women treated with alendronate who had a baseline vertebral fracture (before treatment) and a femoral neck BMD T-score at 5 y that is less than Ϫ2.5, in whom continued alendronate treatment for an additional 5 y (total of 10 y) decreased new vertebral fracture from 11.1% to 5.3% compared with placebo BMD ϭ bone mineral density.
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www.annals.orgtreated with bisphosphonates (85), but another metaanalysis (AMSTAR score, 7 of 11) that included the same 4 studies and 3 additional ones found no association of risk for esophageal cancer with bisphosphonate use (86) . The FDA has not concluded that patients receiving oral bisphosphonate drugs have an increased risk for esophageal cancer. An evaluation of osteosarcoma and teriparatide showed no relationship at 7-year follow-up (87).
Cardiac Risks
An adverse event prominently discussed in 2007 was the potential for bisphosphonate use to cause atrial fibrillation. In 2008, the FDA concluded that "there was no clear association" between bisphosphonate use and atrial fibrillation. Since that time, most (88 -92) but not all (93) original studies and meta-analyses have concluded that there is no increased risk, and concern about atrial fibrillation has faded. A retrospective cohort study using Danish registry data reported on the risk for a diagnosis of heart failure after bisphosphonate prescription. Risk increased with risedronate use and decreased with alendronate use, rendering interpretation of a causal relationship difficult (94) .
Gastrointestinal Side Effects
In our previous review, we did a meta-analysis of adverse events that included 417 randomized trials. In this paper, we identified 31 new articles reporting adverse events, 17 of which contributed to updated pooled analyses (18, 32, 80, (95) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) 
38]).
A network meta-analysis attempted to assess the comparative gastrointestinal safety of bisphosphonates and included 50 RCTs (49 of which were also included in our pooled analyses). For the outcome "treatment discontinuation due to adverse events," this (111) , and the FDA has issued a Risk Evaluation and Mitigation Strategy for the drug. In the largest denosumab trial, there were imbalances between patients treated with denosumab and those receiving placebo for cellulitis, erysipelas, serious ear infections, infective arthritis, and endocarditis. A causal relationship has not been established.
Osteonecrosis of the Jaw
At the time of our previous review, 41 cases of osteonecrosis of the jaw had been identified, nearly all associated with the use of intravenous bisphosphonates. Since that time, 23 publications have assessed this association (112-134) (not counting individual case reports), including a case series of 2408 cases of osteonecrosis of the jaw that found that 88% were associated with intravenous bisphosphonates and 89% of patients were being treated for a malignant condition (135) , a survey of practitioners that estimated an incidence of 28 cases per 100 000 personyears of exposure (129) , and 4 systematic reviews (127, (132) (133) (134) . The most recent of these systematic reviews identified 9 and 12 articles (133, 134) , respectively, of studies about osteonecrosis of the jaw in noncancer patients. The first review (133) (AMSTAR score, 6 of 9) reported that limitations in case definition and the identification of the denominator led to wide variation in the reported incidence, from 0.028% to 4.3%, and these authors refrained from statistical pooling. The second review (134) (AMSTAR score, 6 of 11) pooled 12 studies with high heterogeneity and found an OR of 2.32 (CI, 1.30 to 3.91; I 2 ϭ 41%). This association was of similar magnitude in multiple sensitivity analyses. Osteonecrosis of the jaw has also been reported with denosumab use (26) .
Other
Our pooled analyses showed teriparatide to be associated with an increased risk for hypercalcemia ( and renal-related adverse events have been associated with teriparatide use. Zoledronic acid infusion is associated with a constellation of symptoms that have been described as myalgia, arthralgia, pyrexia, chills, and influenza-like symptoms. A composite of these symptoms has a pooled OR of 6.39 (CI, 5.76 to 7.09). Table 1 displays the results of our pooled analyses of RCTs for all adverse events (adverse events were included if at least 3 trials discussed that event or if the RCTs regarding the event had sample sizes of at least 1000 patients in both the treatment and placebo group).
A study using a national registry in Denmark reported that the risk for inflammatory eye reactions in certain patients treated with bisphosphonates is low (136) . Among women with a prevalent vertebral fracture at baseline and a BMD T-score at 5 years of Ϫ2.5 or less, continued use of alendronate for 5 years decreased the incidence of new clinical vertebral fractures from 11.1% to 5.3%, compared with placebo. The investigators concluded that continuing with alendronate for 10 years instead of stopping after 5 years reduced nonvertebral fracture risk in women without prevalent vertebral fracture whose femoral neck T-scores, achieved after 5 years of alendronate, were Ϫ2.5 or less but did not reduce risk for nonvertebral fracture risk among women without prevalent vertebral fractures whose T-scores were greater than Ϫ2.0 (138).
In the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial, approximately 1200 women who had received zoledronic acid for 3 years were randomly assigned to continue for another 3 years or be switched to placebo. Incidence of radiographically detected vertebral fracture was lower in the patients continuing zoledronic acid (3.0% vs. 6.2% in patients receiving placebo; OR, 0.51 [CI, 0.26 to 0.95]), but there were no differences between groups in clinical vertebral fractures, hip fractures, nonvertebral fractures, or all clinical fractures (139) .
In a recent FDA review on this subject (which involved the FDA's own analysis and pooling of data from these 3 trials with an older and much smaller study of risedronate [140] ), the FDA found that the rate of vertebral and nonvertebral fractures in patients who received bisphosphonates for more than 6 years was 9.3% to 10.6% compared with 8.0% to 8.8% for patients who switched to placebo. The FDA concluded that "these data raise the question of whether continued bisphosphonate therapy imparts additional fracture-prevention benefit, relative to cessation of therapy after 5 years" (141) . In an accompanying commentary, leading osteoporosis experts cautioned that these data came primarily from 2 large studies of alendronate and zoledronic acid, which were subsets of the original randomized cohorts, that they should not be extended to other bisphosphonates, and that FLEX patients with a BMD T-score of Ϫ2.5 or less received added benefits from continuing alendronate therapy beyond 5 years (142).
Dual-Energy X-Ray Absorptiometry Monitoring
Little direct research has been done on the frequency of monitoring for osteoporosis or how often patients should be monitored once they begin antiresorptive therapy. Two population studies of persons not taking osteoporosis treatment showed that frequent monitoring for the development of osteoporosis may not be necessary, except in women with T-score of Ϫ2.0 to Ϫ2.49 (143, 144) . For patients receiving antiresorptive therapy for whom serial BMD measurements have not shown an increase, or have even shown decrease in BMD, statistically significant benefits are still obtained in terms of fracture reduction (145) (146) (147) (148) (149) (150) . Despite a lack of evidence supporting frequent monitoring, one study found that among 549 women being followed at an academic medical center, patients received an average of 3.0 dual-energy x-ray absorptiometry scans over a mean of 2.4 years (for example, an average of Ͼ1 per year). A chart review of a random sample of 92 patients found that, for these women, the primary rationale listed for 177 of 196 scans (90%) was that they were "due"; no treatment change was made after 84% of the scans (151) . This single-site study cannot support strong conclusions, but does highlight the need for more studies about the appropriate use of dual energy x-ray absorptiometry scans.
DISCUSSION
The principal conclusions of this update are presented in Tables 1 and 2 . Compared with the evidence available at the time of the previous report, additional evidence has emerged about differences in antifracture efficacy among pharmacologic agents used to treat osteoporosis. Nonetheless, data about the comparative effectiveness or efficacy among agents are thin, and it is likely that differences among the bisphosphonates, denosumab, and teriparatide are modest. The side effect profiles vary among drugs, but many are associated with gastrointestinal effects. Bisphosphonate and possibly denosumab use carry the risk for very rare side effects, such as atypical subtrochanteric fracture or osteonecrosis of the jaw. There is evidence that women with an initial T-score of Ϫ1.49 or greater do not benefit from repeated BMD reassessment in less than 15 years. Among persons receiving FDA-approved osteoporosis pharmacotherapy, changes in BMD are not good predictors of antifracture effects. Likewise, the optimal duration of therapy remains murky, although evidence suggests that, at least for alendronate, some groups of patients can have the drug safely discontinued after 5 years of treatment.
There are many limitations to our review. The most important of these is the dearth of head-to-head comparisons of the benefits and harms of the agents. This has led several investigators to estimate comparative effectiveness using indirect methods. Although no consistent differences in efficacy have been found, this does not constitute proof that they do not exist. The lack of data in men leaves clinicians and policymakers to try to extrapolate from data in women, which may not be valid. Additional limitations common to all systematic reviews are the possibility of publication bias and heterogeneity in the definition of outcomes and adverse events. Limitations of this review include our reliance on English-language publications and no assessment of costs.
Osteoporosis treatment is an area of very active research. In addition to published studies of new drugs and combinations of drugs being tested for efficacy (152-155), studies are ongoing about the comparative effectiveness of some agents (156), the treatment of men (157) , and the optimal duration of treatment (158). Current author addresses and author contributions are available at www.annals.org.
